Drug Therapy for Generalized Anxiety Disorder Among the Elderly

Completed · Phase 4 · Has a placebo group

Conditions studied: Anxiety Disorders, Generalized Anxiety Disorder

In brief

This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.

Key facts

Study ID

NCT00105586

Run by

University of Pittsburgh

People needed

177

Starts

2004-12-01

Expected to finish

2008-04-01

Last updated by the study team

2017-05-08

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of at least moderately severe generalized anxiety disorder (GAD)

You may not qualify if…

• Serious suicide risk or psychiatric instability that would affect study participation
• Dementia
• Substance abuse, such as alcoholism, within 6 months prior to study entry
• Diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
• Unstable medical conditions that would preclude the use of escitalopram
• Use of certain psychotropics that can not be safely tapered or discontinued for at least 2 weeks prior to and during the study
• Use of neuroleptics that are absorbed over a prolonged period of time within 6 weeks prior to study entry

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.